• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ki-67、p53 和 Survivin 的核染色强度作为非肌肉浸润性膀胱癌的新预后因素。

Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer.

机构信息

Oncology Department, Medical University of Warsaw, 19/25 Stępińska St., 00-739, Warsaw, Poland.

Patomorphology Department, Military Institute of Medicine, 128 Szaserów St., 04-141, Warsaw, Poland.

出版信息

Pathol Oncol Res. 2020 Apr;26(2):1211-1219. doi: 10.1007/s12253-019-00678-1. Epub 2019 Jun 19.

DOI:10.1007/s12253-019-00678-1
PMID:31346958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7242236/
Abstract

The aim of the study was to determine the prognostic value of expression levels of biomarkers selected on the basis of the literature: p53, Ki-67, survivin, β-catenin, E-cadherin and N-cadherin in patients with non-muscle invasive bladder cancer. Immunohistochemistry was performed on sections of primary papillary carcinoma of the bladder removed during transurethral resection of the tumor in 134 patients. The expression of β-catenin and E-cadherin was found in all analyzed cases and N-cadherin expression was demonstrated in 3.73% of the tissues examined. The expression of the p53 protein was confirmed in 96.27% of tissues examined. The expression of the Ki-67 protein was demonstrated in all analyzed cases. Survivin expression was found in 95.52% of the study group. Multivariate analysis confirmed the relationship between the recurrence-free survival (RFS) and the intensity of the nuclear reaction for p53 (HR 1417, 95% CI 1.001-2.007, p = 0.049) and survivin (HR 1.451; 95% CI 1.078-1.955; p = 0.014), the expression level of the Ki-67 protein expressed by the TS index (HR 1.146, 95% CI 1.116-1.823, p = 0.005) and the use of adjuvant BCG therapy (HR 0.218, 95% CI 0.097-0.489, p = 0.0002). The evaluation of Ki-67 expression and the intensity of nuclear staining for survivin and p53 may provide additional information that will allow more accurate stratification of the risk of NMIBC recurrence after TURBT.

摘要

本研究旨在确定基于文献选择的生物标志物表达水平在非肌肉浸润性膀胱癌患者中的预后价值

p53、Ki-67、存活素、β-连环蛋白、E-钙黏蛋白和 N-钙黏蛋白。对 134 例经尿道肿瘤切除术切除的原发性膀胱乳头状癌标本进行免疫组织化学染色。在所有分析的病例中均发现β-连环蛋白和 E-钙黏蛋白的表达,在 3.73%的检查组织中显示 N-钙黏蛋白的表达。在 96.27%的检查组织中证实了 p53 蛋白的表达。所有分析病例均显示 Ki-67 蛋白的表达。在研究组中发现 95.52%的生存素表达。多变量分析证实无复发生存(RFS)与 p53 核反应强度(HR 1417,95%CI 1.001-2.007,p=0.049)和生存素(HR 1.451;95%CI 1.078-1.955;p=0.014)之间存在相关性,Ki-67 蛋白表达水平(TS 指数 HR 1.146,95%CI 1.116-1.823,p=0.005)和辅助 BCG 治疗的使用(HR 0.218,95%CI 0.097-0.489,p=0.0002)。Ki-67 表达和核染色强度的评估,以及生存素和 p53 的表达,可能提供额外的信息,有助于更准确地分层 TURBT 后非肌肉浸润性膀胱癌复发的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13f5/7242236/002a73ead3e7/12253_2019_678_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13f5/7242236/14d4ed605d29/12253_2019_678_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13f5/7242236/002a73ead3e7/12253_2019_678_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13f5/7242236/14d4ed605d29/12253_2019_678_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13f5/7242236/002a73ead3e7/12253_2019_678_Fig2_HTML.jpg

相似文献

1
Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer.Ki-67、p53 和 Survivin 的核染色强度作为非肌肉浸润性膀胱癌的新预后因素。
Pathol Oncol Res. 2020 Apr;26(2):1211-1219. doi: 10.1007/s12253-019-00678-1. Epub 2019 Jun 19.
2
Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer.新预后模型中对非肌肉浸润性膀胱癌患者的部分蛋白表达分析。
J Cancer Res Clin Oncol. 2020 Aug;146(8):2099-2108. doi: 10.1007/s00432-020-03202-0. Epub 2020 Apr 1.
3
Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.p53、p21/WAF1、Bcl-2、Bax、Bak及Ki-67免疫反应性在pT1 G3膀胱尿路上皮癌中的预后价值
Tumour Biol. 2001 Sep-Oct;22(5):328-36. doi: 10.1159/000050635.
4
Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.在根治性膀胱切除术的 pT1 尿路上皮癌患者中,联合免疫组化标志物的预测价值。
J Urol. 2009 Jul;182(1):78-84; discussion 84. doi: 10.1016/j.juro.2009.02.125. Epub 2009 May 17.
5
Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.CK20 和 Ki-67 免疫组化联合分析预测 pT1 尿路上皮膀胱癌的复发、进展和癌症特异性生存。
Eur Urol. 2014 Jan;65(1):218-26. doi: 10.1016/j.eururo.2012.05.033. Epub 2012 May 19.
6
Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.p53、bcl-2和Ki-67在高危浅表性膀胱癌中的预后意义
Anticancer Res. 2002 Nov-Dec;22(6B):3759-64.
7
Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.细胞周期标志物p53、MDM2、p21和Ki-67在浅表性膀胱肿瘤复发中的预测价值
Clin Cancer Res. 1999 Dec;5(12):4079-84.
8
Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma.Ki-67及细胞周期调节因子p53、p63和细胞周期蛋白D1作为膀胱尿路上皮癌复发/进展的预后标志物
Pathol Oncol Res. 2018 Apr;24(2):309-322. doi: 10.1007/s12253-017-0250-2. Epub 2017 May 9.
9
Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder.细胞周期调节蛋白在膀胱浅表性低级别尿路上皮细胞癌中的表达及其预后价值
Eur J Surg Oncol. 2003 Feb;29(1):74-80. doi: 10.1053/ejso.2002.1371.
10
Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.血吸虫病相关的、器官局限型、肌层浸润性膀胱癌:凋亡标志物、增殖标志物、p53、E-钙黏蛋白、表皮生长因子受体及c-erbB-2的预后价值
J Urol. 2001 May;165(5):1481-7.

引用本文的文献

1
Effect of SOX2 gene on the biological characteristics of salivary adenoid cystic carcinoma cells.SOX2基因对涎腺腺样囊性癌细胞生物学特性的影响。
Hua Xi Kou Qiang Yi Xue Za Zhi. 2022 May 25;40(3):341-349. doi: 10.7518/hxkq.2022.03.015.
2
Prediction of Ki-67 expression in bladder cancer based on CT radiomics nomogram.基于CT影像组学列线图预测膀胱癌中Ki-67的表达
Front Oncol. 2024 Feb 28;14:1276526. doi: 10.3389/fonc.2024.1276526. eCollection 2024.
3
Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods.

本文引用的文献

1
Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review.Ki67在卡介苗治疗的非肌层浸润性膀胱癌中的预后价值:一项荟萃分析和系统评价
BMJ Open. 2018 Apr 17;8(4):e019635. doi: 10.1136/bmjopen-2017-019635.
2
Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder.Ki-67标记指数和p53表达状态对膀胱pT1期尿路上皮癌无病生存期的影响。
Transl Androl Urol. 2017 Dec;6(6):1018-1026. doi: 10.21037/tau.2017.11.10.
3
Role of p53 and Ki-67 immunomarkers in carcinoma of urinary bladder.
浸润性腔面乳腺癌中 Ki67 的评估:不同评分方法的比较研究。
Histopathology. 2022 Dec;81(6):786-798. doi: 10.1111/his.14781. Epub 2022 Sep 19.
4
Non-muscle invasive bladder cancer biomarkers beyond morphology.超越形态学的非肌层浸润性膀胱癌生物标志物
Front Oncol. 2022 Aug 3;12:947446. doi: 10.3389/fonc.2022.947446. eCollection 2022.
5
Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen.识别非肌肉浸润性膀胱癌的新预后标志物和治疗靶点:HER2 作为潜在的靶抗原。
Front Immunol. 2022 May 23;13:903297. doi: 10.3389/fimmu.2022.903297. eCollection 2022.
6
Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer.联合 miRNA 和 SERS 尿液液体活检用于膀胱癌的即时诊断和分子分层。
Mol Med. 2022 Apr 1;28(1):39. doi: 10.1186/s10020-022-00462-z.
7
The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer.不同辅助膀胱内治疗方法对高危非肌层浸润性膀胱癌患者肿瘤生物学的影响
Cent European J Urol. 2021;74(4):496-502. doi: 10.5173/ceju.2021.0122. Epub 2021 Oct 22.
8
Prognostic value of Ki-67 in nasopharyngeal carcinoma: a meta-analysis.Ki-67 在鼻咽癌中的预后价值:一项荟萃分析。
Biosci Rep. 2021 May 28;41(5). doi: 10.1042/BSR20203334.
9
Boosting bladder cancer treatment by intravesical nitazoxanide and bacillus calmette-guérin association.通过膀胱内使用硝唑尼特和卡介苗联合治疗增强膀胱癌治疗效果。
World J Urol. 2021 Apr;39(4):1187-1194. doi: 10.1007/s00345-020-03294-w. Epub 2020 Jun 2.
p53和Ki-67免疫标志物在膀胱癌中的作用
Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):505-509. doi: 10.4103/IJPM.IJPM_246_17.
4
Prognostic Value of p53 Expression Intensity in Urothelial Cancers.p53表达强度在尿路上皮癌中的预后价值
J Coll Physicians Surg Pak. 2017 Apr;27(4):232-236.
5
Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.N-钙黏蛋白表达在非肌层浸润性膀胱癌患者中的预后作用。
Urol Oncol. 2017 May;35(5):264-271. doi: 10.1016/j.urolonc.2017.01.012. Epub 2017 Feb 14.
6
Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas.尿路上皮癌中HER/AKT/mTOR信号通路及细胞黏附分子的免疫组织化学研究
Patholog Res Int. 2017;2017:6794150. doi: 10.1155/2017/6794150. Epub 2017 Jan 22.
7
Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.膀胱尿路上皮癌患者的上皮-间质转化及其与临床病理特征的相关性
Clin Genitourin Cancer. 2017 Apr;15(2):e187-e197. doi: 10.1016/j.clgc.2016.07.021. Epub 2016 Aug 9.
8
β-catenin and SKP2 proteins as predictors of grade and stage of non-muscle invasive urothelial bladder carcinoma.β-连环蛋白和SKP2蛋白作为非肌层浸润性尿路上皮膀胱癌分级和分期的预测指标
Chin Clin Oncol. 2016 Feb;5(1):6. doi: 10.3978/j.issn.2304-3865.2016.02.02.
9
Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma.存活素、β-连环蛋白和p53在尿路上皮癌中的表达及其预后意义
Bosn J Basic Med Sci. 2015 Aug 19;15(4):7-14. doi: 10.17305/bjbms.2015.556.
10
p53 Status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with Bacillus Calmette-Guérin: a meta-analysis.p53状态与接受卡介苗治疗的非肌层浸润性膀胱癌的复发风险相关:一项荟萃分析。
PLoS One. 2015 Mar 5;10(3):e0119476. doi: 10.1371/journal.pone.0119476. eCollection 2015.